STIMULI-RESPONSIVE SUPRAMOLECULAR HYDROGELS FOR PACLITAXEL DELIVERY: PROGRESS AND PROSPECTS

Aspects of Molecular Medicine, Journal Year: 2025, Volume and Issue: 5, P. 100062 - 100062

Published: Jan. 5, 2025

---

Revolutionizing Prostate Cancer Therapy: Artificial intelligence – based Nanocarriers for Precision Diagnosis and Treatment

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104653 - 104653

Published: Feb. 1, 2025

Language: Английский

---

Applications of innovative synthetic strategies in anticancer drug Discovery: The Driving Force of new chemical reactions

Bioorganic & Medicinal Chemistry Letters, Journal Year: 2025, Volume and Issue: 119, P. 130096 - 130096

Published: Jan. 9, 2025

Language: Английский

---

Unveiling the Link Between Chronic Inflammation and Cancer

Metabolism Open, Journal Year: 2025, Volume and Issue: 25, P. 100347 - 100347

Published: Jan. 9, 2025

The highly nuanced transition from an inflammatory process to tumorigenesis is of great scientific interest. While it well known that environmental stimuli can cause inflammation, less about the oncogenic modifications chronic inflammation in tissue microenvironment bring about, as how these set off pro-tumorigenic processes. It clear no matter where factors come from, maintaining encourages carcinogenesis. In addition encouraging angiogenesis and metastatic processes, sustaining survival proliferation malignant transformed cells, possibly altering efficacy therapeutic agents, negatively regulate antitumoral adaptive innate immune responses. Because has multiple pathways involved metastasis, gained recognition a marker cancer desirable target for therapy. Recent advances our knowledge molecular mechanisms drive cancer's progression demonstrate promotes metastasis while suppressing anti-tumor immunity. many solid tumor types, including breast, lung, liver cancer, stimulates activation oncogenes impairs body's defenses against tumor. Additionally, alters As tactical approach treatment, findings have underscored importance targeting pathways. This review highlights role development focusing on its impact progression, suppression, therapy resistance. examines current anti-inflammatory strategies, NSAIDs, cytokine modulators, STAT3 inhibitors, addressing their potential limitations. emphasizes need further research unravel complex linking identify targets specific subtypes.

Language: Английский

---

EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 9, 2025

Antibody-drug conjugates (ADCs) are an emerging strategy in cancer therapy, enhancing precision and efficacy by linking targeted antibodies to potent cytotoxic agents. This study introduces a novel ADC that combines ribonuclease A (RNase A) with cetuximab (Cet), anti-EGFR monoclonal antibody, through polyethylene glycol (PEG) linker (RN-PEG-Cet), aimed induce apoptosis KRAS mutant colorectal (CRC) via ROS-mediated pathway. RN-PEG-Cet was successfully synthesized characterized for its physicochemical properties, retaining full enzymatic activity RNA degradation high binding affinity EGFR. In SW-480 cells, significantly reduced cell viability at lower doses, IC50 of 11.7 µg/mL 72 h. Compared free Cet, demonstrated ~ 2-fold increase 3.5-fold ROS production. The conjugate also disrupted the Nrf2/Keap1 pathway, significant upregulation Keap1 (FC = 3.7, p ≤ 0.01) downregulation Nrf2 3.3, < 0.01), highlighting role impairing antioxidant defenses promoting cytotoxicity. These findings emphasize potential as therapeutic approach CRC, offering superior induction cytotoxicity compared conventional therapies. could represent new improving CRC treatment outcomes effectively overcoming resistance mechanisms.

Language: Английский

---

Didemnins as marine-derived anticancer agents: mechanistic insights and clinical potential

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(2)

Published: Jan. 11, 2025

Language: Английский

---

Dendritic cells in triple-negative breast cancer: From pathophysiology to therapeutic applications

Cancer Treatment Reviews, Journal Year: 2025, Volume and Issue: 133, P. 102884 - 102884

Published: Jan. 13, 2025

Breast cancer is the second most commonly diagnosed in women and fifth leading cause of cancer-related deaths worldwide. It a highly heterogeneous disease, consisting multiple subtypes that vary significantly clinical characteristics survival outcomes. Triple-negative breast (TNBC) particularly aggressive challenging subtype cancer. Several immunotherapeutic approaches have been tested patients with TNBC to improve disease outcomes, including administration dendritic cell (DC)-based vaccines. DCs are population play crucial role bridging innate adaptive immune systems. Therefore, increasingly used vaccines due their ability prime boost antigen specific T-cell responses. This review aims provide comprehensive overview TNBC, potential targets pharmacological strategies, as well an relevance TNBC. In addition, we ongoing trials shed light on evolving landscape DC-based immunotherapy for

Language: Английский

---

Cobalt oxide nanoparticles induce cytotoxicity and excessive ROS mediated mitochondrial dysfunction and p53-independent apoptosis in melanoma cells

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 17, 2025

Nanotherapy has emerged as a promising strategy for the targeted and efficient treatment of melanoma, most aggressive lethal form skin cancer, with minimized systemic toxicity. However, therapeutic efficacy cobalt oxide nanoparticles (Co3O4NPs) in melanoma remains unexplored. This study aimed to assess potential Co3O4NPs by evaluating their impact on cell viability, genomic DNA mitochondrial integrity, reactive oxygen species (ROS) generation apoptosis induction A-375 cells. Our findings demonstrated concentration-dependent reduction viability upon five Co3O4NP concentrations (0.2, 2, 20, 200, 2000 µg/ml), an IC50 value 303.80 µg/ml. Treatment this concentration significantly increased ROS generation, induced dramatic damage, disrupted membrane integrity. Flow cytometric analysis revealed necrosis following exposure at value. Results qRT-PCR remarkable dysregulation apoptotic genes, including significant downregulation p53 ND3 genes marked upregulation anti-apoptotic gene Bcl2. These highlight novel potent inducers death manner through excessive production, instability, dysfunction expression, ultimately promoting thus underscores nanotherapeutic candidate treatment, warranting further exploration elucidate full biological clinical applicability.

Language: Английский

---

Current landscape and future directions of therapeutic approaches for adenoid cystic carcinoma of the salivary glands (Review)

Oncology Letters, Journal Year: 2025, Volume and Issue: 29(3)

Published: Jan. 22, 2025

Adenoid cystic carcinoma (ACC) of the salivary glands is second most common type gland cancer, and characterized by a poor prognosis an unclear pathology. The incidence ACC rare, as it accounts for 10-15% all tumors affects mainly patients aged between 50 60 years. annual rate estimated to be ~4.5 cases per 100,000 individuals. Due its rarity use contaminated cell lines in previous investigations, precise etiological factors underlying remain poorly understood. Current treatment modalities, typically involving surgery with or without postoperative radiotherapy, often prove unsatisfactory due potential local recurrence delayed distant metastases, which may manifest 3-5 years after constitute primary failure existing therapeutic approaches. indolent growth pattern, along perineural perivascular invasion, potentially responsible onset metastases. No effective systemic therapy has been established so far. Therefore, management represents significant challenge. Exploring molecular characteristics ACC, including reasons behind propensity invasion correlation immune system, offers promising strategies managing could open up novel pathways future interventions. Currently, immunotherapy shown limited effectiveness. While exact mechanism lack response remains unknown, low levels tumor-infiltrating lymphocytes these contribute this resistance. identifying targets enhance against tumor cells essential. present review provides update on clinical studies explores that ACC.

Language: Английский

---

Unraveling the Role of Fusobacterium nucleatum in Colorectal Cancer: Molecular Mechanisms and Pathogenic Insights

Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 368 - 368

Published: Jan. 23, 2025

Fusobacterium nucleatum, a gram-negative anaerobic bacterium, has emerged as significant player in colorectal cancer (CRC) pathogenesis. The bacterium causes persistent inflammatory reaction the mucosa by stimulating release of pro-inflammatory cytokines like IL-1β, IL-6, and TNF-α, creating an environment conducive to progression. F. nucleatum binds penetrates epithelial cells through adhesins such FadA, impairing cell junctions encouraging epithelial-to-mesenchymal transition (EMT), which is associated with advancement. Additionally, modulates host immune system, suppressing activity conditions favorable for tumor growth. Its interactions gut microbiome contribute dysbiosis, further influencing carcinogenic pathways. Evidence indicates that can inflict DNA damage either directly via reactive oxygen species or indirectly environment. it triggers oncogenic pathways, especially Wnt/β-catenin signaling pathway, promotes growth longevity. Moreover, alters microenvironment, impacting behavior, metastasis, therapeutic responses. purpose this review elucidate molecular mechanisms contributes CRC. Understanding these crucial development targeted therapies diagnostic strategies CRC nucleatum.

Language: Английский

---